BeOne Medicines Has Doubled Off Its Low on Brukinsa’s Growth – but at 64 Times Earnings, the Model Stops at Hold

BeOne Medicines, the cancer drugmaker formerly known as BeiGene, has become a profitable growth company: second-quarter revenue rose 30% to $1.7 billion, led by its blood-cancer drug Brukinsa, and management raised its full-year guidance. The shares have followed, closing at $358.07, roughly double their two-year low. This BeOne Medicines stock analysis, based on Yahoo Finance data as of October 5, 2026, finds high scores for Quality and Growth, but a valuation that leaves our quantitative model’s signal at Hold.

What Is Happening With the Stock Price

At $358.07, BeOne trades in the upper end of its two-year range of $176.50 to $374.47, measured on weekly closes – 102.9% above the low and 4.4% below the high – for a market cap of $40.74 billion. The shares have held near those levels in recent weeks rather than pulling back, a sign that sentiment remains positive after the company beat expectations in August. Analysts have generally followed the move; Barclays, for example, raised its price target to $415 in September while keeping an overweight rating, according to published reports. Price targets are estimates, and a stock this close to its highs has less room for disappointment.

Quality: Is This a Financially Sound Business?

Quality scores 83/100. Gross margin is 88.9%, and Yahoo’s 19.1% operating margin matches the second quarter, when BeOne earned $325.0 million of GAAP operating income on $1.705 billion of revenue, up from $87.9 million a year earlier. Over the trailing twelve months, net profit margin is 10.7%, return on equity 14.7% and return on assets 7.5% – solid figures for a company that only recently moved into sustained profitability.

The balance sheet is a clear strength in this BeOne Medicines stock analysis. The current ratio is 3.40, the quick ratio 2.91 and debt-to-equity 0.40, and the company reported $5.28 billion of cash, cash equivalents and restricted cash against $1.07 billion of debt at the end of June. Free cash flow of $879M over the trailing twelve months shows that profits are converting into cash, giving BeOne room to fund its research pipeline internally.

Growth: Does This Company Have Real Upside?

Growth scores 89/100. Yahoo’s revenue growth figure of 29.6% matches the second quarter’s year-over-year increase, from $1.315 billion to $1.705 billion, while the 55.7% five-year revenue CAGR reflects BeOne’s shift from a largely research-stage company to a commercial one. Brukinsa generated $1.2 billion of global sales in the quarter, up 31%, including $893 million in the U.S., and the cancer immunotherapy Tevimbra added $229 million, up 18%. The 166.7% earnings growth figure matches the rise in second-quarter diluted EPS per ordinary share to $0.16 from $0.06 ($2.05 per ADS, from $0.84).

Management now expects 2026 revenue of $6.6 billion to $6.8 billion and GAAP operating income of $1.0 billion to $1.1 billion. Beyond Brukinsa, the company received U.S. accelerated approval for sonrotoclax in relapsed or refractory mantle cell lymphoma and completed enrollment in a Phase 3 trial of its BTK degrader. With an 88.9% gross margin, an EV/Revenue of 6.14 is a reasonable price for this growth rate.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 21/100, and it is the pillar that sets the signal. A P/E of 64.06 on EPS of $5.59, EV/EBITDA of 35.15, price-to-book of 7.82 and a free-cash-flow yield of 2.2% are all demanding on trailing numbers, and with the shares in the upper end of their range, the model gives little credit for price position. The trailing P/E is high partly because meaningful profits are so new; if guidance is met, earnings would grow into the multiple, but that is not assured. The Recommendation Score of 64/100 is above the model’s 60 threshold for a Buy, yet Opportunity sits below the 30-point minimum the model also requires, so BeOne is rated Hold.

BeOne Medicines Stock Analysis: The Bottom Line

This BeOne Medicines stock analysis ends with a model signal of Hold and a Recommendation Score of 64/100, combining Quality 83/100, Growth 89/100 and Opportunity 21/100. The bull case: revenue growing about 30%, GAAP profits rising quickly, a cash-rich balance sheet, raised guidance and a pipeline that has just produced a newly approved blood-cancer drug. The bear case: Brukinsa accounted for about 70% of second-quarter revenue, so competition in the crowded BTK inhibitor market, pricing pressure on cancer drugs or a clinical setback for pipeline candidates could hit results hard. At 64 times trailing earnings, any slowdown could weigh heavily on the share price.

The Hold label reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact.